公开(公告)号：US11155879B2

公开(公告)日：2021-10-26

申请号：US16490143

申请日：2017-03-01

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Akihiro Ohashi ,  Kenichi Iwai ,  Tadahiro Nambu ,  Ryo Dairiki ,  Yuko Ishii

IPC: C12Q1/6886 ,  A61P35/00 ,  A61K31/519

Abstract: The present invention relates to a method of predicting the likelihood that a patient will respond therapeutically to a pancreatic cancer treatment comprising the administration of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one (Compound 1) and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof, comprising the steps of: STEP (1): determining a KRAS gene mutation status of a sample from a patient, and STEP (2): predicting an increased likelihood that the patient will respond therapeutically to the pancreatic cancer treatment if the patient has the presence of KRAS gene mutation(s), and to methods of treating pancreatic cancer.

公开(公告)号：US20210309712A1

公开(公告)日：2021-10-07

申请号：US17271451

申请日：2019-08-30

Applicant: NOILE-IMMUNE BIOTECH, INC. ,  Takeda Pharmaceutical Company Limited

Inventor： Chihiro TAKE ,  Takayuki TATAMIYA ,  Akiko YAMAGUCHI

IPC: C07K14/725 ,  C07K14/54 ,  C07K14/715 ,  A61K35/17 ,  A61P35/00

Abstract: The present invention provides immune cells (such as CAR-T cells) having higher antitumor activity than immune cells (such as CAR-T cells) expressing a CAR alone (not expressing cytokines and/or chemokines). A T cell provided in one aspect of the present invention expresses (1) a chimeric antigen receptor (CAR), (2) at least one selected from the group consisting of interleukin-15 (IL-15), interleukin-18 (IL-18), interleukin-21 (IL-21), and interleukin-27 (IL-27), and (3) CC chemokine ligand 19 (CCL19).

公开(公告)号：US20210309609A1

公开(公告)日：2021-10-07

申请号：US17350013

申请日：2021-06-17

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takashi Ouchi ,  Giho Goh ,  Sunmi Kim ,  Jinsoon Choi ,  Hunsoo Park

IPC: C07D207/36 ,  B01J23/44 ,  C07B61/00 ,  C07C253/30 ,  C07C255/42 ,  C07D401/12 ,  C07D207/34 ,  B01J8/02 ,  B01J21/04 ,  B01J29/08 ,  C07B31/00 ,  C07B41/06 ,  C07C255/28

Abstract: The present invention provides a production method of a 3-cyanopyrrole compound possibly useful as an intermediate for pharmaceutical products. A production method of compound (II) including subjecting compound (I) to a reduction reaction, in which the aforementioned reduction reaction is continuous hydrogenation reaction in a fixed bed reactor filled with a supported metal catalyst. A production method of compound (III) including subjecting compound (I) to a reduction reaction followed by a cyclization reaction, in which the aforementioned reduction reaction is continuous hydrogenation reaction in a fixed bed reactor filled with a supported metal catalyst.

公开(公告)号：US20210292708A1

公开(公告)日：2021-09-23

申请号：US17265364

申请日：2019-08-02

Applicant: Kyoto University ,  Takeda Pharmaceutical Company Limited

Inventor： Noriko YAMAZOE ,  Hideyuki HIYOSHI ,  Taro TOYODA

IPC: C12N5/00

Abstract: An object of the present invention is to provide a novel approach that enables definitive endoderm cells or insulin-producing cells to be efficiently induced and/or manufactured from pluripotent stem cells. The present invention provides a method for producing definitive endoderm cells from pluripotent stem cells, comprising subjecting pluripotent stem cells to first culture in a differentiation-inducing medium in which insulin acts and subsequently to second culture in a differentiation-inducing medium in which insulin does not act.

公开(公告)号：US20210254014A1

公开(公告)日：2021-08-19

申请号：US17049218

申请日：2019-04-22

Applicant: Kyoto University ,  Takeda Pharmaceutical Company Limited

Inventor： Noriko YAMAZOE ,  Hideyuki HIYOSHI ,  Taisuke MOCHIDA ,  Ryo ITO ,  Taro TOYODA ,  Azuma KIMURA

IPC: C12N5/071 ,  A61K35/39

Abstract: The present invention relates to a method for producing an insulin-producing cell population or a pancreatic β cell population having the reduced number of Ki67-positive cells, comprising treating a population of endocrine progenitor cells or cells at a later stage of differentiation with an FGFR1 inhibitor.

公开(公告)号：US11045457B2

公开(公告)日：2021-06-29

申请号：US16289311

申请日：2019-02-28

Applicant: Takeda Pharmaceutical Company Limited ,  Zacharia Cheruvallath ,  Jason Green ,  Ben Johnson ,  Kristin Schleicher ,  Huikai Sun ,  Mingnam Tang

Inventor： Zacharia Cheruvallath ,  Jason Green ,  Ben Johnson ,  Kristin Schleicher ,  Huikai Sun ,  Mingnam Tang

IPC: C07D207/14 ,  A61K31/4439 ,  A61K31/40 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4468 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  C07D211/58 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D491/048

Abstract: Disclosed are compounds of Formula 1, stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R5, R6, R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

公开(公告)号：US11033550B2

公开(公告)日：2021-06-15

申请号：US16089533

申请日：2017-03-27

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Juran Kato ,  Hiroko Yamakawa ,  You Muraki ,  Gattu Mahanandeeshwar ,  Oruganty Satyalakshmi

IPC: A61K31/519 ,  A61P9/12

Abstract: An object of the present invention is to provide a medicament for preventing or treating pulmonary hypertension. The present invention provides a medicament for preventing or treating pulmonary hypertension, comprising a compound selected from the group consisting of (5R)-N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)-N-[1-ethyl-1-(4-methoxyphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)-N-[1-ethyl-1-(4-ethylphenyl)propyl]-5-(2-fluorophenyl)-2,7,7-trimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, and the salt thereof.

公开(公告)号：US11028048B2

公开(公告)日：2021-06-08

申请号：US16777273

申请日：2020-01-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yasushi Hattori ,  Yuhei Miyanohana ,  Yuichi Kajita ,  Tatsuki Koike ,  Yasutaka Hoashi ,  Norihito Tokunaga ,  Alexander Martin Pawliczek ,  Tsuneo Oda ,  Tohru Miyazaki ,  Marilena Pira ,  Javier Miguelez-Ramos

IPC: C07D207/14 ,  C07D407/08 ,  C07D417/06

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20210130305A1

公开(公告)日：2021-05-06

申请号：US16935531

申请日：2020-07-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Keisuke HIRAI ,  Takashi ISHIKAWA

IPC: C07D263/52 ,  A61K31/428 ,  A61K31/423 ,  A61P25/00 ,  C07D277/60 ,  C07D413/06

Abstract: The present invention provides a prophylactic or therapeutic agent for an autism spectrum disorder containing compound (I) having melatonin receptor affinity. A compound represented by the formula: wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20210115048A1

公开(公告)日：2021-04-22

申请号：US16608723

申请日：2018-04-26

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuji KITAMURA ,  Zenichi IKEDA ,  Minoru IKOMA ,  Koji WATANABE ,  Hideki HIROSE ,  Takafumi YUKAWA ,  Sachie MORIMOTO ,  Naoki NISHIZAWA ,  Taiji ASAMI

IPC: C07D487/04 ,  A61P9/04 ,  A61K47/38 ,  A61K31/4184 ,  A61K9/48 ,  A61K9/20

Abstract: The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification.